Moderna, Merck cancer combo cuts melanoma spread risk at five years

Moderna and Merck said their combination therapy for skin cancer reduced the risk of cancer spreading to another part of the body by 59% after five years of follow-up in a mid-stage trial. The result supports the treatment’s efficacy signal and is positive for both companies’ oncology pipelines. The data are clinically meaningful, though still early-stage and not yet a regulatory readout.

Analysis

Moderna and Merck said their combination therapy for skin cancer reduced the risk of cancer spreading to another part of the body by 59% after five years of follow-up in a mid-stage trial. The result supports the treatment’s efficacy signal and is positive for both companies’ oncology pipelines. The data are clinically meaningful, though still early-stage and not yet a regulatory readout.